Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment
Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...
Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...
Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid...
Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD)...
Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...
Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has...